Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Actions01:26

Antibody Actions

3.4K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.4K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

1.1K
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.1K
Affinity and Avidity01:41

Affinity and Avidity

40.0K
Overview
40.0K
Antidotes01:17

Antidotes

1.3K
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
1.3K
Conjugated Proteins02:50

Conjugated Proteins

29.6K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
29.6K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

5.2K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies.

The AAPS journal·2020
Same author

Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies.

The AAPS journal·2020
Same author

Monitoring of the deuterated and nondeuterated forms of levodopa and five metabolites in plasma and urine by LC-MS/MS.

Bioanalysis·2019
Same author

Measurement of lidocaine and 2,6-dimethylaniline in minipig plasma, skin, and dermal tapes using UHPLC with electrospray MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2018
Same author

Liquid chromatographic-tandem mass spectrometry assay for the quantification of MDT-637 in human nasal wash.

Biomedical chromatography : BMC·2018
Same author

Validation of an LC-MS/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2018

Related Experiment Video

Updated: Mar 19, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K

Antibody drug conjugates.

Ray Bakhtiar1

  • 1Teva Branded Pharmaceutical Products R & D Inc, West Chester, PA, 19380, USA. rbakhtiar@msn.com.

Biotechnology Letters
|June 24, 2016
PubMed
Summary
This summary is machine-generated.

Antibody drug conjugates (ADCs) offer targeted cancer therapy. Newer generations of ADCs aim to improve drug specificity and efficacy through advanced conjugation techniques.

Keywords:
Brentuximab vedotinChemical linkersConjugationCytotoxicityPayloadSolid tumorsTranstuzumab emtansine

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Related Experiment Videos

Last Updated: Mar 19, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Area of Science:

  • Oncology
  • Biotechnology
  • Pharmacology

Background:

  • Antibody drug conjugates (ADCs) represent a promising strategy for targeted delivery of potent cytotoxic agents in solid tumor treatment.
  • Currently, only two ADCs are approved, with over 40 in clinical development, highlighting the field's rapid expansion.
  • First-generation ADCs faced limitations due to non-specific conjugation, resulting in heterogeneous drug-to-antibody ratios.

Purpose of the Study:

  • To provide an overview of recent advancements in Antibody Drug Conjugate (ADC) development.
  • To discuss the current challenges and limitations in the field of ADC therapeutics.
  • To highlight the potential of next-generation ADCs in overcoming existing technical hurdles.

Main Methods:

  • Review of current literature and clinical trial data.
  • Analysis of technological platforms and antibody engineering advancements.
  • Examination of conjugation chemistries, linkers, and payload candidates.

Main Results:

  • Second-generation ADCs are utilizing site-specific conjugation methods, including enzymatic ligation and unnatural amino acids, to enhance specificity.
  • Innovations in antibody engineering, novel linkers, and new payload options are expanding the potential of ADCs.
  • The clinical trial landscape shows significant activity, with approximately 270 studies related to ADCs.

Conclusions:

  • Site-specific conjugation strategies are crucial for improving the therapeutic index of ADCs.
  • Continued technological progress in antibody engineering and chemistry is driving the development of more effective ADC therapies.
  • Addressing current challenges in ADC development is essential for realizing their full potential in cancer treatment.